GSK’s 3 billion pounds sterling peak sales goal for its multiple myeloma drug Blenrep appears increasingly attainable thanks ...

GSK's drive to resurrect its multiple myeloma therapy Blenrep has continued with new data from the DREAMM-7 trial showing an ...

Cambridge, USA-based Vesalius Therapeutics has entered into a multi-target strategic alliance with the UK’s GSK to discover ...

GSK is paying $80 million to ink a multi-target neurodegenerative pact with Flagship-founded Vesalius Therapeutics that ...

Under deal terms, GSK will give Vesalius Therapeutics $80 million in upfront and equity payments to identify treatments for ...

In its third quarter results of 2024, pharmaceutical giant GSK confirmed it would pay a quarterly dividend of 15 pence. However, Morningstar analyst Christopher Johnson says he believes that GSK’s ...

The drugmaker’s U.S. plans comes on the heels of a rough quarter, with lower vaccine demand driving down Q3 sales by 15% year ...

CureVac Announces Financial Results for the Third Quarter and First Nine Months of 2024 and Provides Business Update. Strengthened Cash, Strategic Refocus and Pipeline Progress De ...

The agreement will see GSK pay $300m upfront to acquire full global rights to CMG1A46, and Chimagen will be eligible to receive success-based development and commercial milestone payments totalling ...

GlaxoSmithKline (GSK ... Discover how AI is transforming the pharma commercial strategy. Unlock real-time insights & actions from data. Click here for more. In the age of AI, large data sets ...

GlaxoSmithKline (GSK) has agreed to acquire Chimagen Biosciences’ CMG1A46, a clinical-stage therapy designed to target B cell ...